Document Detail

Gabapentin to pregabalin therapy transition: a pharmacokinetic simulation.
MedLine Citation:
PMID:  23018586     Owner:  NLM     Status:  MEDLINE    
The objective of this modeling study was to assess different dosage regimens that might be used to guide clinicians in transitioning patients from gabapentin to pregabalin therapy when such a transition is clinically warranted. Two different gabapentin to pregabalin transition designs were simulated based on their respective population pharmacokinetic profiles. The first design involved immediate discontinuation of gabapentin therapy with initiation of pregabalin therapy at the next scheduled dose period. The second design featured a gradual transition involving coadministration of 50% of the gabapentin dosage and 50% of the desired pregabalin dosage for 4 days, followed by discontinuation of gabapentin and fully targeted dosages of pregabalin. Both transition designs were studied at 3 dosage levels: gabapentin 900 mg/d to pregabalin 150 mg/d, gabapentin 1800 mg/d to pregabalin 300 mg/d, and gabapentin 3600 mg/d to pregabalin 600 mg/d. Overall drug exposure achieved during the 2 transition designs was the sum of the gabapentin and pregabalin concentrations, expressed as pregabalin-equivalent concentrations. The pharmacokinetic simulations show that during the transition period in both designs, predicted pregabalin-equivalent concentrations did not depart from those calculated during periods of steady-state gabapentin or pregabalin monotherapy. Transition from gabapentin to pregabalin was seamless and rapid, with predicted pregabalin-equivalent concentrations highly comparable with plasma pregabalin concentrations within 1 day of pregabalin initiation in the immediate discontinuation model and within 1 day of gabapentin cessation in the gradual discontinuation model. These data suggest that transitioning patients from gabapentin to pregabalin could theoretically be achieved by either of the 2 approaches assessed.
Howard N Bockbrader; Meeta N Budhwani; David L Wesche
Related Documents :
23356886 - Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therap...
10604296 - Low-dose postoperative transconjunctival application of mitomycin c in rabbit trabecule...
24698366 - Metformin use decreases the anticoagulant effect of phenprocoumon.
23149786 - A light field-based method to adjust rounded leaf end mlc position for split shape dose...
22756556 - Su-e-t-377: dose calculation accuracy of various commercially available algorithms for ...
15477496 - Neuropathology in rhinosinusitis.
Publication Detail:
Type:  Evaluation Studies; Journal Article    
Journal Detail:
Title:  American journal of therapeutics     Volume:  20     ISSN:  1536-3686     ISO Abbreviation:  Am J Ther     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-09     Completed Date:  2013-06-17     Revised Date:  2013-08-21    
Medline Journal Info:
Nlm Unique ID:  9441347     Medline TA:  Am J Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  32-6     Citation Subset:  IM    
BEP Analyses, Ann Arbor, MI, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amines / administration & dosage,  pharmacokinetics*
Anticonvulsants / administration & dosage,  pharmacokinetics*
Computer Simulation*
Cyclohexanecarboxylic Acids / administration & dosage,  pharmacokinetics*
Drug Administration Schedule
Drug Substitution
Models, Biological*
gamma-Aminobutyric Acid / administration & dosage,  analogs & derivatives*,  pharmacokinetics
Reg. No./Substance:
0/Amines; 0/Anticonvulsants; 0/Cyclohexanecarboxylic Acids; 55JG375S6M/pregabalin; 56-12-2/gamma-Aminobutyric Acid; 6CW7F3G59X/gabapentin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Approach to a Successful Selection of Antihypertensive Drugs for the Patient With Atherosclerosis.
Next Document:  Differences in Systemic and Skin Migrating-Specific CD4 T Cells in Papular Urticaria by Flea Bite.